New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
08:18 EDTDSCODiscovery Labs reports Q2 EPS (12c), consensus (15c)
Reports Q2 revenue $1.09M, consensus $580.000. Included in the EPS net loss is the change in fair value of certain common stock warrants that are classified as derivative liabilities, resulting in non-cash income of $1.4M.
News For DSCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
07:36 EDTDSCODiscovery Labs enrolls first patient in Aerosurf Phase 2a dose expansion trial
Subscribe for More Information
May 14, 2015
09:22 EDTDSCOOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Perry Ellis (PERY), up 11.5%... (CTRP), up 13.4%. ALSO HIGHER: AcelRx (ACRX), up 10.3% after being awarded contract worth up to $17M from Defense Dept to advance ARX-04... Oncothyreon (ONTY), up 16.9% after ASCO presentation data released... CYREN (CYRN), up 14.6% after announcing agreement with Dell.... Discovery Laboratories (DSCO), up 5.2% after Aerosurf shows positive Phase 2a data... Kate Spade (KATE), up 3.9% after being initiated with an Outperform at Wedbush. DOWN AFTER EARNINGS: Digital Ally (DGLY), down 16.4%... Kohl's (KSS), down 10.2%... VOXX (VOXX), down 8.1%... Cosi (COSI), down 7.3%. ALSO LOWER: Biotechnology (PBYI), down 15.1%% after Neratinib data published in ASCO abstract... Gevo (GEVO), down 10.7% after 4.3M share Spot Secondary priced at $4.00.
07:11 EDTDSCODiscovery Labs's Aerosurf shows positive Phase 2a data
Discovery Laboratories reported top line data from its recently completed Aerosurf phase 2a clinical trial in premature infants with respiratory distress syndrome. Key objectives of the study were achieved, including the primary objective of demonstrating the safety and tolerability of a single exposure of aerosolized KL4 surfactant administered in three escalating inhaled doses to premature infants 29 to 34 week gestational age and receiving nasal continuous positive airway pressure for RDS, and establishing proof of concept for the company's proprietary technology platform. The company plans to start a phase 2a dose expansion in 29 to 34 weeks gestational age infants to evaluate increased doses and repeat dosing in Q2 with completion in Q4, a phase 2a clinical trial assessing the safety and tolerability of escalating doses of AEROSURF administered to 26 to 28 weeks gestational age infants, anticipated to begin in July with completion in Q4, and a phase 2b clinical trial to determine the optimal dose and define the expected efficacy margin of AEROSURF treatment in Q4 with completion in mid 2016.
May 13, 2015
10:07 EDTDSCOHigh option volume stocks
Subscribe for More Information
09:56 EDTDSCOEquity options with increasing volume
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use